RxDoctor Payments Data

Ajay Dalal, MD

Cardiovascular Disease · Germantown, TNNPI 1770583239

Payments from drug & device makers

$860in general payments, 2019–2025

Across 20 payments — averaging $43.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Terumo Medical Corporation$283
  • Abbott$155
  • Amgen$125
  • Heartflow, Inc.$118
  • E.r. Squibb & Sons, L.L.C.$93
  • Medtronic$27
  • plus $59 from 3 others

What the payments were for

  • Travel & lodging$16619%
  • Food & beverage$60570%
  • Education$9010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 30th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$143,743
Medicare patients
1,395
Services billed
2,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$85,389
EntrestoSacubitril/Valsartan53$52,940
Ranolazine ErRanolazine440$32,779
XareltoRivaroxaban22$23,038
Repatha SureclickEvolocumab27$15,161
FarxigaDapagliflozin Propanediol11$10,311
JardianceEmpagliflozin11$7,901
BrilintaTicagrelor11$5,540
LivaloPitavastatin Calcium11$5,216
Atorvastatin Calcium421$4,333
Pitavastatin Calcium48$4,217
Ezetimibe168$3,937
Metoprolol Succinate255$3,411
Carvedilol151$1,444
Metoprolol Tartrate239$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$85,38987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →